By Brad Sorensen, CFA
NASDAQ: HCTI
Healthcare Triangle’s (NASDAQ: HCTI) planned spin-off of Teyame AI Holdings represents an interesting new chapter in the company’s transformation. Rather than simply selling the rapidly growing AI-powered customer engagement operation that has become an increasingly important part of Healthcare Triangle, or HCTI, management is pursuing a structure that could allow investors to participate in the value of Teyame in two different ways. Existing HCTI shareholders are expected to receive shares directly in Teyame, while HCTI itself plans to retain a majority ownership interest in the business.
For investors, understanding that structure is particularly important. This is not presently contemplated as a complete separation in which HCTI gives away or disposes of its entire Teyame investment. Instead, HCTI intends to distribute a minority percentage of Teyame AI Holdings to HCTI shareholders on a pro rata basis and retain the majority of Teyame's outstanding shares. Following the transaction, Teyame is expected to become a separately traded public company through a planned Nasdaq direct listing.
That distinction creates what could be an attractive value-unlocking opportunity.
HCTI acquired Teyamé 360 S.L. and Datono Mediación S.L. earlier in 2026 through Teyame AI Holdings. Together, the businesses operate an integrated platform providing AI-powered omnichannel customer experience, marketing and financial and insurance distribution services. Teyame combines artificial intelligence with contact-center and telemarketing capabilities to assist enterprises with customer acquisition, retention and customer service, while Datono adds insurance brokerage and distribution capabilities.
The acquisition has already dramatically changed HCTI's financial profile. During the second quarter of 2026, HCTI generated $9.19 million of revenue, an increase of 158% from the year-earlier period, while gross profit increased 322% to $2.07 million. The AI-powered customer engagement segment contributed approximately $6.31 million, or roughly 69%, of quarterly revenue. Companywide gross margin expanded to 22.5% from 13.8% a year earlier.
Those numbers help explain why separating Teyame into its own publicly traded company could be strategically significant.
The stock market does not always assign full value to individual businesses operating underneath a single corporate umbrella. Investors interested primarily in healthcare IT may value HCTI differently from investors seeking exposure to artificial intelligence, customer engagement or automation. When the businesses are combined, the market effectively has to arrive at a single valuation for very different assets.
Creating an independently traded Teyame could change that dynamic.
Once Teyame has its own listing, investors should have a much clearer market reference for the value being assigned to the AI customer-engagement operation. Instead of Teyame being represented only as one segment within HCTI's consolidated financial statements, the business could have its own share price, market capitalization, financial reporting and investor following.
That could make HCTI's retained stake particularly interesting.
The September 2 separation agreement specifically states that HCTI intends to remain the majority shareholder of Teyame after the distribution. HCTI also received extensive registration rights covering the Teyame shares it retains, including demand, shelf and piggyback registration rights. Those provisions could eventually provide HCTI with flexibility to monetize some of its Teyame ownership if management determines that doing so would be beneficial.
This creates the possibility of a relatively straightforward sum-of-the-parts valuation for investors. Following the listing, the market could potentially identify the value of HCTI's ownership in Teyame simply by looking at Teyame's publicly quoted valuation and applying HCTI's ownership percentage. HCTI's remaining healthcare technology, cloud, cybersecurity, data engineering and managed-services businesses could then effectively represent another layer of value.
For a relatively small public company, that type of transparency can be meaningful.
Another important feature is that the relationship between HCTI and Teyame will not abruptly end when Teyame begins operating as a separate public company. Under a transition services agreement, HCTI is expected to provide Teyame with accounting, administrative, human resources, legal, compliance, contracting, procurement and information technology services. Teyame will compensate HCTI for these services.
That arrangement should help Teyame transition toward independence without immediately having to recreate every corporate function internally. It could also provide HCTI with some service revenue while allowing the companies to maintain operational continuity.
Perhaps more importantly, majority ownership means HCTI should continue to have substantial economic exposure to Teyame's future growth. The SEC filing specifically contemplates that HCTI may continue consolidating Teyame's financial results depending upon the applicable accounting requirements. Teyame has agreed to provide the financial information HCTI needs for consolidated reporting for as long as those requirements remain applicable.
As presented, the strategic logic of management is encouraging. HCTI acquired a business that materially expanded its revenue base and strengthened its exposure to artificial intelligence. Instead of simply absorbing Teyame indefinitely or selling the operation outright, management is attempting to establish an independent market valuation for the business while retaining majority ownership and sharing part of that ownership directly with HCTI investors.
If successfully completed, the transaction could make the underlying value of Teyame far more visible, provide HCTI with a potentially valuable publicly traded strategic asset, and give existing shareholders direct participation in the future of both companies. For investors evaluating HCTI, that makes the Teyame separation and Nasdaq listing one of the company's most significant potential valuation catalysts to watch over the coming months.
SUBSCRIBE TO ZACKS SMALL CAP RESEARCH to receive our articles and reports emailed directly to you. Please visit our website for additional information on Zacks SCR.
DISCLOSURE: Zacks SCR has received compensation from the issuer directly, from an investment manager, or from an investor relations consulting firm, engaged by the issuer, for providing research coverage for a period of no less than one year. Research articles, as seen here, are part of the service Zacks SCR provides and Zacks SCR receives payments totaling a maximum fee of up to $50,000 annually for these services provided to or regarding the issuer. Full Disclaimer HERE.